New drug duo tested for Tough-to-Treat cervical cancer
NCT ID NCT04865887
Summary
This study is testing whether combining two existing drugs, pembrolizumab and lenvatinib, can help control advanced cervical cancer that has worsened after standard treatment. It will involve about 35 women to see if the combination shrinks tumors and for how long. The goal is to find a new treatment option for cancer that has stopped responding to first-line therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgia Cancer Center at Augusta University
RECRUITINGAugusta, Georgia, 30912, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
John Theurer Cancer Center at Hackensack UMC
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MedStar Georgetown University Hospital
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Medstar Washington Hospital Center
WITHDRAWNWashington D.C., District of Columbia, 20010, United States
Conditions
Explore the condition pages connected to this study.